Status:
COMPLETED
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
Lead Sponsor:
AbbVie
Conditions:
Progressive Supranuclear Palsy (PSP)
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
Eligibility Criteria
Inclusion
- Subject completed Study C2N-8E12-WW-104 (NCT02494024)
- Subject was not eligible to enroll in Study M15-562 (NCT02985879)
Exclusion
- Subject weighs less than 35 kg at screening
- Subject has any contraindication or inability to tolerate brain MRI
- Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results
Key Trial Info
Start Date :
April 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 20 2019
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03413319
Start Date
April 17 2018
End Date
November 20 2019
Last Update
December 3 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San /ID# 170113
La Jolla, California, United States, 92093
2
Texas Health Physicians Group /ID# 170112
Dallas, Texas, United States, 75218